RxDoctor Payments Data

Jerry Hunsaker, MD

Ophthalmology · Corpus Christi, TXNPI 1194705319

Payments from drug & device makers

$1,668in general payments, 2019–2025

Across 75 payments — averaging $22.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1000
  • Amgen$207
  • Alcon$144
  • Sun Pharmaceutical Industries Inc.$142
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$47
  • Thea Pharma Inc.$41
  • plus $87 from 4 others

What the payments were for

  • Food & beverage$1,63698%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,668 in reported general payments places this provider in the 45th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$373,581
Medicare patients
1,308
Services billed
3,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost303$139,517
RestasisCyclosporine28$27,261
ProlensaBromfenac Sodium59$20,082
CombiganBrimonidine Tartrate/Timolol46$16,699
RocklatanNetarsudil Mesylat/Latanoprost40$15,711
Prednisolone Acetate276$14,225
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol76$13,030
Brimonidine Tartrate139$12,297
XiidraLifitegrast18$11,855
VyzultaLatanoprostene Bunod25$11,739
Alphagan PBrimonidine Tartrate22$11,050
RhopressaNetarsudil Mesylate32$10,217
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat580$9,872
Travoprost62$9,076
Latanoprost1,022$8,945

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$1,000$194,527399 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$23$23,59443 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$47$22,20774 claims
AlconSimbrinza$144$2,60613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →